Document is current
Any future updates will be listed below
-
Authors
Kimura, Shun-ichi https://orcid.org/0000-0001-9827-8526
Fujita, Hiroyuki
Handa, Hiroshi
Hiramoto, Nobuhiro
Hosono, Naoko
Minamiguchi, Hitoshi
Takahashi, Tsutomu
Kato, Hideaki
Ono, Takaaki
Kanda, Yoshinobu
Kiyoi, Hitoshi
Matsumura, Itaru
Miyazaki, Yasushi
,
- License Information
-
More Information
Article History
Received: 29 April 2020
Revised: 5 June 2020
Accepted: 11 June 2020
First Online: 18 June 2020
Compliance with ethical standards
:
: Shun-ichi Kimura received personal fees from Asahi Kasei, Sumitomo Dainippon Pharma, MSD, Astellas, Pfizer, Kyowa Kirin, Chugai Pharmaceutical Co.,Ltd., Bristol-Myers Squibb, Celgene, Ono Pharmaceutical Co.,Ltd., Eisai Co., Ltd. and Nippon Kayaku. Hiroyuki Fujita received personal fees from Asahi Kasei, Sumitomo Dainippon Pharma, MSD, Astellas, Pfizer, Kyowa Kirin, Chugai and Bristol-Myers Squibb. Hitoshi Minamiguchi received personal fees from Astellas, Celgene, and Ono Pharmaceutical Co.,Ltd. Tsutomu Takahashi received personal fees from Kyowa Kirin, Chugai Pharmaceutical Co.,Ltd., Bristol-Myers Squibb and Celgene. Takaaki Ono received grant from Celgene, Kyowa Hakko Kirin, Chugai Pharamaceutical Co.,Ltd. and Merck Sharp & Dohme, and personal fees from Celgene, Merck Sharp & Dohme, Novartis, Bristol-Myers Squibb, Pfizer and Otsuka Pharmaceutical Co., Ltd. Yoshinobu Kanda received personal fees from Astellas, Sumitomo Dainippon Pharma, Chugai Pharamaceutical Co.,Ltd., Pfizer, Eisai Co., Ltd., Kyowa Kirin, Takeda Pharmaceutical Company Limited., Ono Pharmaceutical Co.,Ltd., and Sionogi & Co., Ltd. Hitoshi Kiyoi received grant from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., Perseus Proteomics Inc. and Celgene Corporation, and personal fees from Astellas Pharma Inc., Amgen Astellas BioPharma K.K., Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K. Itaru Matsumura received grant from Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Pfizer Japan Inc., MSD K.K, Astellas Pharma Inc., Japan Blood Products Organization, CSL Behring, TEIJIN PHARMA LIMITED., Bristol-Myers Squibb Company, Janssen Pharmaceutical K.K, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., ASAHI KASEI PHARMA CORPORATION, Takeda Pharmaceutical Company Limited., NIPPON SHINYAKU CO.,LTD., TAIHO PHARMACEUTICAL CO., LTD., Mitsubishi Tanabe Pharma Corporation, NIHON PHARMACEUTICAL CO., LTD, Nippon Kayaku Co.,Ltd., Novartis Pharma KK, DAIICHI SANKYO COMPANY, LIMITED., Amgen Astellas BioPharma K.K., Otsuka Pharmaceutical Co., Ltd., JCR Pharmaceuticals Co., Ltd., Mundipharma K.K., AbbVie GK., Sanofi K.K., AYUMI Pharmaceutical Corporation, Eli Lilly Japan K.K., and Actelion Pharmaceuticals Japan Ltd., and personal fees from Pfizer Japan Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical K.K, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Novartis Pharma KK, DAIICHI SANKYO COMPANY, LIMITED., Amgen Astellas BioPharma K.K., Otsuka Pharmaceutical Co., Ltd., AbbVie GK., Sanofi K.K., and Actelion Pharmaceuticals Japan Ltd. Yasushi Miyazaki received personal fees from Ono Yakuhinn, ASTELLAS, SynBio, Otsuka, Janssen, Chugai, Novartis, Abbvie, Celgene, Bristol-Myers Squib, Eisai, Daiichi-Sankyo, Kyowa-Kirin, Dainippon-Sumitomo, Nippon-Shinyaku, TAKEDA, and Pfizer. Other authors: none to declare.
